GGrantIndex
← Leaderboards

Channing J Der

University Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$34,774,720
Attributed
$39,637,584
Total exposure
22
Grants
18
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.7M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$47,495,394 · 23

By mechanism

R01$18,605,813 · 8
P01$9,389,031 · 5
T32$7,078,228 · 2
R35$6,311,775 · 1
P50$2,633,196 · 2
U01$2,457,493 · 1

Top collaborators

Others in their field

Top investigators on “Mutation”

Research focus

MutationMalignant NeoplasmsSignal TransductionGrowthMutantCancer TherapyCancer CellMalignant Neoplasm Of PancreasKras2 GeneCancer EtiologyBaseCessation Of LifeTumorigenesisPathway InteractionsMouse ModelPharmaceutical PreparationsInhibitor/AntagonistProtein KinaseMeksTargeted TreatmentProtein IsoformsBiologicalOncogenesPancreatic Ductal Adenocarcinoma

Grant awards (127)

Project 1: Targeting autophagy for the treatment of KRAS-mutant PDAC$448,515
P50 · FY2025 · CA · contact PI
Cancer Cell Biology Training Program$251,339
T32 · FY2025 · CA · contact PI
Targeting undruggable RAS for cancer treatment$865,656
R35 · FY2024 · CA · contact PI
Project 1: Targeting autophagy for the treatment of KRAS-mutant PDAC$432,936
P50 · FY2024 · CA · contact PI
Cancer Cell Biology Training Program$332,856
T32 · FY2024 · CA · contact PI
Targeting undruggable RAS for cancer treatment$902,485
R35 · FY2023 · CA · contact PI
Project 1: Targeting autophagy for the treatment of KRAS-mutant PDAC$415,212
P50 · FY2023 · CA · contact PI
Cancer Cell Biology Training Program$314,720
T32 · FY2023 · CA · contact PI
Targeting undruggable RAS for cancer treatment$899,999
R35 · FY2022 · CA · contact PI
The Role of RHOA in Diffuse Gastric Cancer$787,791
R01 · FY2022 · CA
Project 1: Targeting autophagy for the treatment of KRAS-mutant PDAC$467,623
P50 · FY2022 · CA · contact PI
Targeting undruggable RAS for cancer treatment$921,017
R35 · FY2021 · CA · contact PI
The Role of RHOA in Diffuse Gastric Cancer$819,369
R01 · FY2021 · CA
Defining RAS isoform- and mutation-specific roles in oncogenesis$1,609,444
P01 · FY2020 · CA · contact PI
Integrated Training in Cancer Model Systems$935,418
T32 · FY2020 · CA · contact PI
Targeting undruggable RAS for cancer treatment$918,610
R35 · FY2020 · CA · contact PI
The Role of RHOA in Diffuse Gastric Cancer$677,302
R01 · FY2020 · CA
Administrative and biostatistics core$147,090
P01 · FY2020 · CA · contact PI
Project 1: Mutation-specific vulnerabilities for KRAS-targeted therapy$117,318
P01 · FY2020 · CA · contact PI
Admin-Core-001$74,339
P01 · FY2020 · CA · contact PI
Defining RAS isoform- and mutation-specific roles in oncogenesis$1,491,448
P01 · FY2019 · CA · contact PI
Integrated Training in Cancer Model Systems$918,827
T32 · FY2019 · CA · contact PI
Targeting undruggable RAS for cancer treatment$894,826
R35 · FY2019 · CA · contact PI
The Role of RHOA in Diffuse Gastric Cancer$656,983
R01 · FY2019 · CA
Identification of synthetic lethal interactors in pancreatic cancer$323,651
U01 · FY2019 · CA · contact PI
Administrative and biostatistics core$160,081
P01 · FY2019 · CA · contact PI
Project 1: Mutation-specific vulnerabilities for KRAS-targeted therapy$139,601
P01 · FY2019 · CA · contact PI
Defining RAS isoform- and mutation-specific roles in oncogenesis$64,809
P01 · FY2019 · CA · contact PI
Admin-Core-001$64,809
P01 · FY2019 · CA · contact PI
Defining RAS isoform- and mutation-specific roles in oncogenesis$1,539,964
P01 · FY2018 · CA · contact PI
Targeting undruggable RAS for cancer treatment$909,182
R35 · FY2018 · CA · contact PI
Integrated Training in Cancer Model Systems$793,807
T32 · FY2018 · CA · contact PI
The Role of RHOA in Diffuse Gastric Cancer$677,302
R01 · FY2018 · CA
Identification of synthetic lethal interactors in pancreatic cancer$316,801
U01 · FY2018 · CA · contact PI
Mechanisms of PAK1 activation, signaling and tumor resistance$243,190
R01 · FY2018 · CA · contact PI
Administrative and biostatistics core$146,561
P01 · FY2018 · CA · contact PI
Project 1: Mutation-specific vulnerabilities for KRAS-targeted therapy$121,972
P01 · FY2018 · CA · contact PI
Defining RAS isoform- and mutation-specific roles in oncogenesis$1,542,424
P01 · FY2017 · CA · contact PI
Integrated Training in Cancer Model Systems$789,141
T32 · FY2017 · CA · contact PI
Mechanisms of PAK1 activation, signaling and tumor resistance$406,839
R01 · FY2017 · CA · contact PI
Biological Activity of Ras Oncogenes$349,678
R01 · FY2017 · CA · contact PI
Identification of synthetic lethal interactors in pancreatic cancer$340,086
U01 · FY2017 · CA · contact PI
Administrative and biostatistics core$146,295
P01 · FY2017 · CA · contact PI
Project 1: Mutation-specific vulnerabilities for KRAS-targeted therapy$124,398
P01 · FY2017 · CA · contact PI
Defining RAS isoform- and mutation-specific roles in oncogenesis$1,609,721
P01 · FY2016 · CA · contact PI
Identification of synthetic lethal interactors in pancreatic cancer$732,247
U01 · FY2016 · CA · contact PI
Mechanisms of PAK1 activation, signaling and tumor resistance$424,266
R01 · FY2016 · CA · contact PI
Biological Activity of Ras Oncogenes$369,223
R01 · FY2016 · CA · contact PI
Administrative and biostatistics core$151,347
P01 · FY2016 · CA · contact PI
Project 1: Mutation-specific vulnerabilities for KRAS-targeted therapy$137,410
P01 · FY2016 · CA · contact PI
Identification of synthetic lethal interactors in pancreatic cancer$744,708
U01 · FY2015 · CA · contact PI
Biological Activity of Ras Oncogenes$370,723
R01 · FY2015 · CA · contact PI
Mechanisms of PAK1 activation, signaling and tumor resistance$361,887
R01 · FY2015 · CA · contact PI
Cancer Cell Biology Training Program$270,447
T32 · FY2015 · CA · contact PI
ERK inhibitor resistance and ERK isoform-dependent growth in pancreatic cancer$174,780
R21 · FY2015 · CA · contact PI
Mechanisms of PAK1 activation, signaling and tumor resistance$370,739
R01 · FY2014 · CA · contact PI
Biological Activity of Ras Oncogenes$346,184
R01 · FY2014 · CA · contact PI
ERK inhibitor resistance and ERK isoform-dependent growth in pancreatic cancer$231,887
R21 · FY2014 · CA · contact PI
Cancer Cell Biology Training Program$196,202
T32 · FY2014 · CA · contact PI
Biological Activity of Ras Oncogenes$335,477
R01 · FY2013 · CA · contact PI
Cancer Cell Biology Training Program$238,995
T32 · FY2013 · CA · contact PI
Biological Activity of Ras Oncogenes$356,891
R01 · FY2012 · CA · contact PI
Mechanism and role of DLC-1 tumor suppressor loss in lung cancer$296,590
R01 · FY2012 · CA · contact PI
Cancer Cell Biology Training Program$204,581
T32 · FY2012 · CA · contact PI
Genetic dissection and inhibitor targeting of Rac signaling in pancreatic cancer.$160,950
R21 · FY2012 · CA · contact PI
Biological Activity of Ras Oncogenes$356,891
R01 · FY2011 · CA · contact PI
Mechanism and role of DLC-1 tumor suppressor loss in lung cancer$296,590
R01 · FY2011 · CA · contact PI
Role of RGS proteins in Ras- and B-Raf--mediated transformation$214,543
R01 · FY2011 · CA · contact PI
Genetic dissection and inhibitor targeting of Rac signaling in pancreatic cancer.$193,140
R21 · FY2011 · CA · contact PI
Mechanism and role of DLC-1 tumor suppressor loss in lung cancer$305,763
R01 · FY2010 · CA · contact PI
Role of RGS proteins in Ras- and B-Raf--mediated transformation$221,178
R01 · FY2010 · CA · contact PI
Cancer Cell Biology Training Program$188,294
T32 · FY2010 · CA · contact PI
Biological Activity of Ras Oncogenes$176,966
R01 · FY2010 · CA · contact PI
Biological activity of ras oncogenes$319,853
R01 · FY2009 · CA · contact PI
Mechanism and role of DLC-1 tumor suppressor loss in lung cancer$305,763
R01 · FY2009 · CA · contact PI
Validation of Inhibitors of RhoGTPases for Cancer Treatment$259,101
U19 · FY2009 · CA · contact PI
Role of RGS proteins in Ras- and B-Raf--mediated transformation$221,178
R01 · FY2009 · CA · contact PI
Cancer Cell Biology Training Program$194,752
T32 · FY2009 · CA · contact PI
Biological activity of ras oncogenes$319,853
R01 · FY2008 · CA · contact PI
Mechanism and role of DLC-1 tumor suppressor loss in lung cancer$300,879
R01 · FY2008 · CA · contact PI
Role of RGS proteins in Ras- and B-Raf--mediated transformation$221,178
R01 · FY2008 · CA · contact PI
Cancer Cell Biology Training Program$196,303
T32 · FY2008 · CA · contact PI
TARGETING THE RAS>ERK PATHWAY FOR COLORECTAL CANCER TREATMENT$172,525
P50 · FY2008 · CA · contact PI
Biological activity of ras oncogenes$319,853
R01 · FY2007 · CA · contact PI
Rho Family Proteins and Malignant Transformation$259,037
R01 · FY2007 · CA · contact PI
TARGETING THE RAS>ERK PATHWAY FOR COLORECTAL CANCER TREATMENT$243,911
P50 · FY2007 · CA · contact PI
Role of RGS proteins in Ras- and B-Raf--mediated transformation$221,178
R01 · FY2007 · CA · contact PI
Cancer Cell Biology Training Program$211,676
T32 · FY2007 · CA · contact PI
Biological activity of ras oncogenes$329,406
R01 · FY2006 · CA · contact PI
Rho Family Proteins and Malignant Transformation$266,774
R01 · FY2006 · CA · contact PI
Ras Signal Transduction and Transformation$251,773
R01 · FY2006 · CA · contact PI
TARGETING THE RAS>ERK PATHWAY FOR COLORECTAL CANCER TREATMENT$151,295
P50 · FY2006 · CA · contact PI
Cancer Cell Biology Training Program$143,282
T32 · FY2006 · CA · contact PI
Biological activity of ras oncogenes$337,334
R01 · FY2005 · CA
Rho Family Proteins and Malignant Transformation$273,194
R01 · FY2005 · CA
Ras Signal Transduction and Transformation$257,832
R01 · FY2005 · CA
Aberrant LARG and RhoA activation in human leukemias$240,450
R01 · FY2005 · CA
CANCER CELL BIOLOGY TRAINING PROGRAM$162,205
T32 · FY2005 · CA
TARGETING THE RAS>ERK PATHWAY FOR COLORECTAL CANCER TREATMENT$152,739
P50 · FY2005 · CA
BIOLOGICAL ACTIVITY OF RAS ONCOGENES$333,255
R01 · FY2004 · CA
Rho Family Proteins and Malignant Transformation$273,194
R01 · FY2004 · CA
Ras Signal Transduction and Transformation$257,832
R01 · FY2004 · CA
Aberrant LARG and RhoA activation in human leukemias$240,450
R01 · FY2004 · CA
CANCER CELL BIOLOGY TRAINING PROGRAM$162,676
T32 · FY2004 · CA
TARGETING THE RAS>ERK PATHWAY FOR COLORECTAL CANCER TREATMENT$148,440
P50 · FY2004 · CA
BIOLOGICAL ACTIVITY OF RAS ONCOGENES$323,548
R01 · FY2003 · CA
Rho Family Proteins and Malignant Transformation$267,994
R01 · FY2003 · CA
Ras Signal Transduction and Transformation$257,832
R01 · FY2003 · CA
Aberrant LARG and RhoA activation in human leukemias$240,450
R01 · FY2003 · CA
CANCER CELL BIOLOGY TRAINING PROGRAM$169,736
T32 · FY2003 · CA
BIOLOGICAL ACTIVITY OF RAS ONCOGENES$314,124
R01 · FY2002 · CA
Ras Signal Transduction and Transformation$280,082
R01 · FY2002 · CA
Aberrant LARG and RhoA activation in human leukemias$240,450
R01 · FY2002 · CA
RHO FAMILY PROTEINS AND MALIGNANT TRANSFORMATION$213,778
R01 · FY2002 · CA
CANCER CELL BIOLOGY TRAINING PROGRAM$154,319
T32 · FY2002 · CA
ADAPTIVE IMMUNOTHERAPY--LONG CIRCULATING MACROMOLEC$0
U19 · FY2002 · CA
Convergence / Divergence of G Protein Signals through PLC-epsilon$0
P01 · FY2002 · GM
BIOLOGICAL ACTIVITY OF RAS ONCOGENES$309,475
R01 · FY2001 · CA
Aberrant LARG and RhoA activation in human leukemias$259,312
R01 · FY2001 · CA
RHO FAMILY PROTEINS AND MALIGNANT TRANSFORMATION$207,616
R01 · FY2001 · CA
CANCER CELL BIOLOGY TRAINING PROGRAM$136,708
T32 · FY2001 · CA
ADAPTIVE IMMUNOTHERAPY--LONG CIRCULATING MACROMOLEC$0
U19 · FY2001 · CA
BIOLOGICAL ACTIVITY OF RAS ONCOGENES$323,994
R01 · FY2000 · CA
RHO FAMILY PROTEINS AND MALIGNANT TRANSFORMATION$201,566
R01 · FY2000 · CA
RAS SIGNAL TRANSDUCTION AND TRANSFORMATION$192,961
R01 · FY2000 · CA
CANCER CELL BIOLOGY TRAINING PROGRAM$111,944
T32 · FY2000 · CA
ADAPTIVE IMMUNOTHERAPY--LONG CIRCULATING MACROMOLEC$0
U19 · FY2000 · CA